Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (161-170 of 282) with videos related to

Pageof 29
Sort By:
Prostate Cancer and Prostatic Diseases|November 3, 2018
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy seriesJames L Mohler, Susan Halabi, Stephen T Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate CancerSantosh Gupta, Susan Halabi, Qian Yang, et al.
Prostate Cancer and Prostatic Diseases|April 1, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)Santosh Gupta, Siyuan Guo, Susan Halabi, et al.
The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.
Targeted Oncology|October 17, 2020
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Elizabeth Garrett-Mayer, Susan Halabi, et al.
JCO Precision Oncology|January 4, 2019
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPam K Mangat, Susan Halabi, Suanna S Bruinooge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialToni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck, Joellen M Schildkraut, Robert M Wenham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2024
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or EnzalutamideSusan Halabi, Siyuan Guo, Joseph J Park, et al.
The Oncologist|March 13, 2020
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology DrugsErin P Balogh, Andrew B Bindman, S Gail Eckhardt, et al.
Pageof 29

Showing results (161-170 of 282) with videos related to

Sort By:
Pageof 29
Prostate Cancer and Prostatic Diseases|November 3, 2018
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy seriesJames L Mohler, Susan Halabi, Stephen T Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate CancerSantosh Gupta, Susan Halabi, Qian Yang, et al.
Prostate Cancer and Prostatic Diseases|April 1, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)Santosh Gupta, Siyuan Guo, Susan Halabi, et al.
The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.
Targeted Oncology|October 17, 2020
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Elizabeth Garrett-Mayer, Susan Halabi, et al.
JCO Precision Oncology|January 4, 2019
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPam K Mangat, Susan Halabi, Suanna S Bruinooge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialToni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck, Joellen M Schildkraut, Robert M Wenham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2024
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or EnzalutamideSusan Halabi, Siyuan Guo, Joseph J Park, et al.
The Oncologist|March 13, 2020
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology DrugsErin P Balogh, Andrew B Bindman, S Gail Eckhardt, et al.
Pageof 29